Skip to content

Multiple Myeloma

US Focus Meeting 2026

📍 Boston, MA

🗓️ August 14 - 15, 2026

Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Multiple Myeloma Focus Meeting 2026, to be held at on August 14 - 15, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Multiple Myeloma research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.  

 

Chairs of Multiple Myeloma US Focus Meeting 2026:

Noopur-Raje

Noopur Raje, MD
Massachusetts General Hospital, Boston, MA


Shaji-Kumar

Shaji Kumar, MD
Mayo Clinic, Rochester, MN


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
freya.symons@md-education.com

Agenda & Faculty

August 14, 2026 | Day 1  

08:10 AM
Registration Opens
08:45 AM
Welcome and Introduction

Session VII: Early-Stage CRC
Moderated by:

Noopur-Raje

Noopur Raje, MD
Massachusetts General Hospital, Boston, MA

09:00 AM
Role of Mass Spectrometry in Screening, Diagnosis, and Disease Monitoring
David-L-Murray
David L. Murray, MD
Mayo Clinic, Rochester, MN
09:15 AM
Can We Replace FISH Panel with Sequencing?
Mehmet-K-Samur
Mehmet K. Samur, MD
Dana-Farber Cancer Institute, Boston, MA
09:30 AM
MRD Monitoring in MM – Current Approaches
Nikhil-Munshi
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA
09:45 AM
Panel Discussion
10:15 AM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
10:30 AM
Coffee Break

Session II: Management of Precursor Conditions
Moderated by:

Nikhil-Munshi

Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA

10:50 AM
Monoclonal Gammopathy – Diagnosis and Risk Adapted Approach to Monitoring
Natalie-Callander
Natalie Callander, MD
UW Health, Madison, WI
11:05 AM
Smoldering Multiple Myeloma – Current Approaches to Management
Sagar-Lonial
Sagar Lonial, MD
Emory Winship Cancer Institute, Atlanta, GA
11:20 AM
Monoclonal Gammopathies – When Are They of Clinical Significance?
Vincent-Rajkumar
Vincent Rajkumar, MD
Mayo Clinic, Rochester, MN
11:35 AM
Panel Discussion
12:05 PM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
12:20 PM
01:05 PM
Industry Supported Independent Expert Discussion
Lunch Break

Session III: Other Plasma Cell Disorders
Moderated by:

Shaji-Kumar

Shaji Kumar, MD
Mayo Clinic, Rochester, MN

01:55 PM
Management of Light Chain Amyloidosis
Anita-DSouza
Anita D’Souza, MD
Medical College of Wisconsin, Wauwatosa, WI
02:10 PM
Waldenström Macroglobulinemia
Prashant-Kapoor
Prashant Kapoor, MD
Mayo Clinic, Rochester, MN
02:25 PM
Panel Discussion
02:55 PM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
03:10 PM
Coffee Break

Session IV: Newly Diagnosed Multiple Myeloma
Moderated by:

Tom-Martin

Tom Martin, MD
UCSF Health, San Francisco, CA

03:30 PM
Integrating T-Cell Redirection Therapy into Newly Diagnosed MM Treatment
Surbhi-Sidana
Surbhi Sidana, MD
Stanford Medicine, CA
03:45 PM
Does Transplant Have a Role in the Management of Myeloma – Upfront or Later?
Amrita-Krishnan
Amrita Krishnan, MD
City of Hope, Duarte, CA
04:00 PM
Defining Frailty and Making Treatment Decisions
Ashley-Rosko
Ashley Rosko, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH
04:15 PM
Panel Discussion & Take-Home Points from Day 1
04:45 PM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
05:00 PM
Adjourn

August 15, 2026 | Day 2

08:00 AM
Registration Opens

Session V: Individualizing Therapy in Myeloma – Role of Risk Stratification
Moderated by:

Elias-Jabbour

Shaji Kumar, MD
Mayo Clinic, Rochester, MN

09:00 AM
How Do We Adapt Treatment to Baseline
Saad-Usmani
Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY
09:15 AM
Integrating Response into Treatment Decisions
Luciano-Costa
Luciano Costa, MD
UAB Medicine, Birmingham, AL
09:30 AM
Management of Extramedullary Decisions
Wilson-Gonsalves
Wilson Gonsalves, MD
Mayo Clinic, Rochester, MN
09:45 AM
Panel Discussion & Take-Home Points from Day 1
10:15 AM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
10:30 AM
Coffee Break

Session VI: Management of Initial Relapse: Part 1
Moderated by:

Nikhil-Munshi

Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA

10:50 AM
When Should We Start Treatment for Relapse?
Jonathan-Kaufman
Jonathan Kaufman, MD
Emory Winship Cancer Institute, Atlanta, GA
11:05 AM
Treatment at First Relapse – IMiD-PI-anti- CD38 Based Combinations Should Be First Choice
Binod-Dhakal
Binod Dhakal, MD
Medical College of Wisconsin, Wauwatosa, WI
11:20 AM
CAR-T Should Be the Treatment of Choice
Doris-Hansen
Doris Hansen, MD
Moffitt Cancer Center, FL
11:35 AM
12:05 PM
12:50 PM
Panel Discussion
Industry Supported Independent Expert Discussion
Lunch Break

Session VII: Management of Initial Relapse: Part 2
Moderated by:

Noopur-Raje

Noopur Raje, MD
Massachusetts General Hospital, Boston, MA

01:40 PM
Bispecific Antibody Should Be the Treatment of Choice
Krina-Patel
Krina Patel, MD
Moffitt Cancer Center, FL
01:55 PM
ADC Should Be the Treatment Choice
Suzanne-Trudel
Suzanne Trudel, MD
The Princess Margaret Cancer Centre, Toronto, Canada
02:10 PM
Panel Discussion
02:40 PM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
02:55 PM
03:15 PM
Coffee Break
Industry Supported Independent Expert Discussion

Session VIII: Management of Late Relapse
Moderated by:

Saad-Usmani

Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY

04:00 PM
Novel Approaches to TCE Therapies - Bispecifics and Trispecifics
Andrew-Yee
Andrew Yee, MD
Massachusetts General Hospital, Boston, MA
04:15 PM
Novel CAR-T Cell Approaches
Tom-Martin
Tom Martin, MD
UCSF Health, San Francisco, CA
04:30 PM
Targeted Therapies in MM - Moving Beyond Immunotherapy
Joshua-Richter
Joshua Richter, MD
Icahn School of Medicine at Mount Sinai, New York, NY
04:45 PM
Panel Discussion & Take-Home Points from Day 2
05:15 PM
Case Discussion and Q&A

TBD

Fellow / Junior Faculty
05:30 PM
Adjourn

Freya Symons
Project Manager

How long has Freya Symons been in the business?

Freya Symons has been with MD Education since 2025. 

About Freya Symons

 

Freya-Symons-Web